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Introduction
Genetically engineered (GE) insects, such as the GE OX513A Aedes aegypti mosquitoes, have
been designed to suppress their wild-type populations so as to reduce the transmission of vec-
tor-borne diseases in humans. Apart from the ecological and epidemiological uncertainties
associated with this approach, such biotechnological approaches may be used by individual
governments or the global community of nations to avoid addressing the underlying struc-
tural, systemic causes of those infections [1]. For instance, the rise in the number of Zika infec-
tions in northeastern Brazil is the product of the interaction of multiple factors. A key element
is the 2015 El Niño climate phenomenon (in the context of global warming). A recent Human
Rights Watch Report identified other factors responsible for the spread of the infection as the
failure of the state to make adequate investment in piped water and waste services for the indi-
gent segments of its population and to address racism and socioeconomic health disparities
[1]. The report also criticized the violation of sexual and reproductive rights in Brazil. How-
ever, a detailed discussion of these structural, systemic factors lies beyond the scope of this Pol-
icy Platform, which is based on our expertise in healthcare ethics, political philosophy,
feminist philosophy, medical entomology, insect–pathogen interactions, innovations in the
control of vector-borne diseases, risk assessment, and environmental ethics.
We discuss here key ethical questions raised by the use of GE insects, with the aim of foster-
ing discussion between the public, researchers, policy makers, healthcare organizations, and
regulatory agencies at the local, national, and international levels. We affect that goal by outlin-
ing a procedural approach to decision-making about the use of the “biotechnology” that goes
beyond “community engagement.” The protocol we advocate for entails informed delibera-
tions and decision-making at the community level. It is designed to ensure that the voices of
the marginalized and vulnerable groups that would be disproportionately affected by the deci-
sion are heard during the community-wide discussions. Moreover, we make the case that the
values embedded in the risk assessment should be identified so that the community can make
an informed decision about the use of GE insects. In addition, we advocate for the involvement
of a variety of actors whose responsibility would be to ensure that the community has the
opportunity to make an informed decision based on deliberations about the use of the
“biotechnology.”
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GE insects: An emerging risk
The use of the GE insects in field trials or for the purposes of control of disease vectors qualifies
as an emerging risk. The International Risk Governance Council has indeed defined “emerg-
ing risks” as those about which there is significant uncertainty and a low level of knowledge
about the potential effect of and interactions with the system into which they are introduced
[2]. Thus, rigorous risk assessment of the GE insect is crucial, as the affected community
would need it to decide whether it would want the insect to be used in its neighborhood [3].
Released males GE OX513A (Box 1) are expected to out compete the wild males to mate
successfully with their female wild-type counterpart. Of the resulting progeny, 96% are not
expected to survive [4]. Consequently, after multiple releases over time, the population of the
mosquito in the release area is expected to significantly decrease, which, presumably, will result
in the decrease in the spread of the Aedes-transmitted arbovirus in humans. While the plan is
to release billions of engineered mosquitoes [5] and given that (as of October 2017) at least 90
million GE OX513A A. aegypti mosquitoes have been released in various nations during field
trials, and approximately 4% of that population of GE insect may have survived without tetra-
cycline [4], it is worrisome that, as of yet, there are no published peer-reviewed studies about
the fitness of that subpopulation of GE insects or its progeny. Moreover, as of yet, there are no
peer-reviewed published studies about the epidemiological efficacy of this mosquito that dem-
onstrate that field trials resulted in lower incidence of disease in humans.
Communities and informed decision-making
While it would be judicious to employ known-to-be-effective methods of disease vector con-
trols [6], there is a push by some nonstate actors to develop and use GE insects [see, for
instance, 7]. Nations with high-disease burden should be able to autonomously decide on the
soundness of the “use” of GE insects, without undue influence from nonstate actors or other
countries. They will shoulder the risks and harms from the use of GE insects. But the question
of informed decision-making has relevance beyond the release area, as the A. aegypti mosquito
has been inadvertently transported substantial distances in vehicles [8, 9]. Migration of GE
mosquitoes over national borders could have serious international political implications.
Community advisory boards (CABs) have been proposed as a means for local community
engagement [10]. In the context of international collaborative research in poorer nations, com-
munity engagement is praised as an indicator of sound ethical and research practice. However,
there is a dearth of published research on models of effective engagement or methods for eval-
uating them [11, 12]. In fact, it appears that community engagement may have been used in
some instances by developers of GE mosquitoes, working in conjunction with local govern-
ment officials and agencies to ensure that affected populations perceive the “biotechnology” in
a positive light and consent to its use [13]. In addition, the CAB model of community engage-
ment may not necessarily be sensitive or responsive to power differential based on gender,
race, ethnicity, age, nationality, class, or social status between CAB members, which might
affect participants’ engagement in discussions [9] and, presumably, decision-making.
Given the limitations of CABs, in the interest of substantive community engagement, we
propose a two-step approach to informed decision-making, which we term “Community
Deliberations and Decision-Making” (CDD). Our approach recognizes that respect for the
fundamental principle of democracy requires that affected parties be provided with the oppor-
tunity to make decisions about normative matters that impact them. The CDD protocol is also
designed to be attentive and responsive to the power differential among groups within com-
munities. So the aim of the CDD would be to provide the affected population with the oppor-
tunity to make an informed decision about whether they would want GE mosquitoes released
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in their neighborhood. But that would only be possible if government officials maintain a strict
commitment to serve as the watchdogs of public health and the environment; they have a fidu-
ciary duty to the people only. Thus, government agencies must subject claims by sponsors of
new “products” to careful and rigorous scrutiny. (If government officials fail to be responsive
to their duty to the public, in democracies, the people then have the ability to remove them
from their office.) We also advocate for further research about the variety of complex norma-
tive elements that may come into play during field trials and open releases but which cannot
be addressed in this Policy Platform.
As the first stage of the two-step CDD approach, the regional government, in conjunction
with the relevant local grassroots nongovernmental organizations (NGOs) (for instance, orga-
nizations that advocate for women’s access to healthcare and which are unaffiliated with any
entities involved in the development or sale of the GE insect), should invite representatives of
the relevant populations constituting the community to participate in a series of forums about
the use of the biotechnology. In the case of communities facing the threat of Zika, indigent
females, specifically girls and women of childbearing age, are a significant relevant population,
as they are the ones who could be infected with the virus during pregnancy [1]. Moreover,
given traditional gender roles and inadequate social support, as mothers, they will bear the
lion share of the enormous responsibility of caring and providing for the children harmed by
the illness [14]. Given all that is at stake for indigent women of childbearing age, it would be
critical to include them in the forums and for their stance to be given particular weight. Efforts
should be made by the entities overseeing the forums (specifically, regional government enti-
ties, and local NGOs) to ensure that those women are afforded recognition in the forums as
the equals of the other participants. Inequitable power relations between them and other
groups in that community or nation must not be reinstantiated in the forums that are used to
augment democratic processes.
The forum sessions should include consultations with experts in risk assessment and insect
vectors of disease who are unaffiliated with the developers of the GE mosquito. We have two
worries about the presence of specialists associated with the developers of the GE insect at the
forum consultations. First, their presence might inhibit participants from openly articulating
their concerns. Second, the experts affiliated with the organizations that sponsored the GE
insect might present themselves to the forum participants as having greater epistemic authority
than the unaffiliated experts, undermining the latter’s epistemic credibility and thus having an
undue influence over the deliberations and decision-making. Thus, we propose that GE mos-
quito developers share all their data in a transparent manner as requested by the independent
Box 1. The GE mosquito: How does it work?
The GE OX513A Aedes aegypti has been subject to a germline modification that includes
a lethality gene. Specifically, a synthetic genetic sequence encoding a tetracycline-
repressible transcriptional activator (tTAV) is introduced into the mosquito with the
intent of creating tetracycline dependency in the insect. In the absence of tetracycline,
tTAV is expressed, and this leads to the death of most of the mosquitoes carrying the
trait [4]. If tetracycline is present (as it is during the mosquito rearing in the laboratory,
for example), then tTAV is repressed and the larvae can develop and reach adulthood.
Female mosquitoes are the biters that spread the disease, so only the male GE mosqui-
toes are intended for release in the target area.
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experts and answer any questions they might have about their research if they are called on by
them. The cost of the forums’ consultation with the unaffiliated experts should be borne by the
sponsoring entity of the GE insect.
The onus would be on the independent specialists to evaluate the risk assessments provided
by the sponsor of the GE mosquito and explain its significance to the forum members (which,
presumably, would be constituted of laypersons). The values that shaped the risk evaluation,
ranging from hazard identification to dose-response modeling to exposure assessment to risk
characterization [15] would have to be identified. That would enable the members of the
forum to make an informed decision about the use of the GE mosquito. For instance, is the
risk evaluation predicated on the normative assumption that it is acceptable that a percentage
of GE mosquitoes (and their progeny) might survive and establish a GE population in the local
ecosystem even though the long-term impact of that possibility on the ecosystem is not
known? Does the risk assessment favor the use of the new “biotechnology” whose ultimate
effectiveness remains unproven even though evidence-based, effective, sustainable, and
cheaper approaches are available?
The second step in the informed decision-making process would involve community wide
discussions and decision-making [16, 17]. (The forums are proposed as a tool for augmenting
democratic processes to ensure that marginalized and vulnerable groups that might be dispro-
portionately affected by the decision about the use of a GE mosquito are not drowned out in
democratic processes wherein majoritarianism prevails; their rationale and decision would be
shared with the larger community as it deliberated on the use of the “biotechnology” and it
must take them into account as it makes its decision.)
The community level decision-making would have to be prefaced by an iterative delibera-
tive process wherein members of the community along with scientists, public health experts,
policy makers, and regulatory agency personnel would identify their normative concerns and
justify their stance to each other (see [17] on democratic engagement). The sessions would
provide participants with the opportunity to engage with each other by framing and reframing
ethical and sociopolitical issues. They would also have “space” to articulate and examine the
new normative concerns and questions that might emerge.
We want to acknowledge that the community members would hear the independent scien-
tific experts’ analysis of the risk assessment of the use of the GE mosquito (relative to that of
other approaches to controlling the spread of arboviruses or their vectors) in an emotionally
and normatively charged context (specifically, they may be fearful about the spread of the
arboviruses or their emergence, and they may subscribe to particular religious or cultural val-
ues). However, since the community will be affected by the choice to use or not use the GE
mosquito, it must make that decision.
We also want to recognize that the affected community may include a diversity of stand-
points and interests. However, we believe it is possible for community members to deliberate
and decide about matters of common concern. After all, democratic deliberations and deci-
sion-making occur at many levels and in many nations even though the participants have var-
ied interests, values, and political agendas. The key issue is that the process of deliberations
and decision-making should be fair, and the results should not reinstantiate or create inequita-
ble power relations among the groups within the community.
With respect to GE animals with gene drives, their release in the wild should necessarily be
preceded by global deliberations and decision-making. Depending on its genetic characteris-
tics, a gene drive cassette could spread in an entire population and affect it within a fairly short
timespan [18] leading to unwanted repercussions across ecosystems on multiple species whose
“ways of life” [19] are mutually entangled [20].
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Cost of the patented GE insect
The cost of the “biotechnology” is another key ethical issue. Initially, the Oxitec GE mosquito
had been classified by the United States Food and Drug Administration (FDA) as a pharmaceu-
tical product, albeit a new animal drug. But in October 2017, the agency handed regulatory
authority to the US Environmental Protection Agency (EPA), which intends to regulate the
insect as a “pesticide.” The transfer of regulatory jurisdiction was justified on the grounds that
the GE mosquito had been classified as a pesticide by Oxitec. In October 2017, the FDA issued a
guidance document for industry that the EPA would have jurisdiction over mosquitoes catego-
rized as “pesticides” and the FDA would regulate GE insects that were construed as ‘products’
that were “intended to prevent mosquito-borne disease in humans or animals.” However, the
change in regulatory jurisdiction and the classification of the GE mosquito as a pesticide does
not change the fact that it is meant to reduce or prevent the transmission of arboviruses in
humans, and thus, it is a public health “tool.” That raises the following question for poorer
nations: How much will the GE insects cost and how will local or federal governments pay for
them? The cost is likely to be significant for those nations and will eat into their budgets (Box 2).
The use of the GE insect raises another related complex ethical, socio-political and legal
issue complicating the biological ones. At least 4% of the GE insects will survive even in
absence of tetracycline. If they establish outside of the target area, then questions must be
asked about the extent of the patent holders’ power. To appreciate how the judicial systems of
various nations may treat such cases it might be useful to consider the (partially) analogous
case of patented GM (genetically modified) seed (Box 3).
Box 2. GE mosquitoes in Piracicaba
The Oxitec GE mosquito is projected to cost the Brazilian city of Piracicaba (with a pop-
ulation of 391,449) approximately US$1.1 million over a two-year period at the cost of
US$10 per person in the target area (50% of the cost will be financed by the city’s current
mosquito control budget; Oxitec will be subsidizing some portion of the cost, presum-
ably, to build a market for its “product”) [4]. The use of the GE mosquito will require
recurrent relicensing from the patent owning company [5]. However, this estimate
seems relatively low compared to a recent one that suggests that the cost of using the
Oxitec GE mosquito for an urban population of 50,000 would be approximately US$1.9
million in the first year and US$384,000 each year thereafter [21]. While different situa-
tions and contexts may naturally lead to different costs of intervention, the discrepancy
is troubling, given the importance of reliable and accurate financial information for
informed discussions and choices by concerned communities and public health authori-
ties, especially in countries that have stringent limits on their public health budgets.
Box 3. Patents and GE organisms
In Canada and the US, the courts have invariably sided with the patent holder in the case
of genetic drift (i.e., the migration of GM seed into farmland meant to grow non-GM
plants) [22]. In Monsanto Canada Inc. versus Schmeiser, the Canadian Supreme Court
found farmer Percy Schmeiser guilty of patent infringement, even though there was
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The US and Canadian courts could consider the rulings in the genetic drift cases as the rele-
vant precedent. So if a habitat of GE insects is found in a nontarget area, then the courts could
accept the patent-holding corporation’s argument that the owner of that property was “using”
its “product” without paying for it. With respect to other nations, given that one of the key
aims of the World Trade Organization (WTO) is to protect the rights of patent-holding enti-
ties, it may rule in favor of them in disputes involving inadvertent “use” of the GE insects by a
WTO member nation. That kind of “use” is likely if the releases are in border regions because
borders of nations arbitrarily carve up ecosystems.
The enforcement of the right of patent-holding entities in cases where the affected nations
have not consented to the “use” of the “pesticide” presents a thorny political and economic
problem for poorer nations. Patent-holding corporations could demand additional fees from
those countries, claiming that they are “using” its product. Given that their budgets are already
strained, those costs could further undermine those nations’ capacity to provide basic necessi-
ties for their population [24]. They may even have to take out additional loans from transna-
tional financial institutions to pay those costs, worsening their national debt burden.
Conclusion
We have identified the complexity of some of the moral issues and the need for concerted,
comprehensive local, national, and global efforts to find effective, efficient, and ethical solu-
tions for reducing the transmission of arboviruses. We have focused primarily on the use of
the GE mosquito OX513A, but our analysis is relevant for the larger category of gene drive-
based approaches for insects and other animals.
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